RE: ESMO poster now on Avacta website19 Oct 2025 15:33
How could it not become the standard of care??
"These data highlight three important findings for the pre|CISION® platform: first, the elimination of the cardiac signal even at higher cumulative doses demonstrates that pre|CISION® is capable of protecting normal tissues from toxicity. Second, the activity in a tumor type without FAP on the tumor cells confirms the bystander effect of pre|CISION® and third, the tumor concentration data even at low FAP expression opens up an even greater number of cancer types to the platform.
“This development, combined with the recent update on our first dual payload peptide drug conjugate, underscores the tremendous potential of our proprietary pre|CISION® technology pipeline to deliver meaningful benefits for patients.”